不同化疗方案在非小细胞肺癌患者治疗中的应用

The application of different chemotherapy regimens in non-small cell lung cancer

目的探讨GP方案（顺铂联合吉西他滨）与NP方案（顺铂联合长春瑞滨）治疗晚期非小细胞癌的临床应用效果。方法回顾性分析86例非小细胞肺癌患者的临床资料,其中GP方案治疗45例,NP方案治疗41例。比较两组临床疗效、生存期及毒副反应。结果 GP组与NP组治疗总有效率分别为44.4%和36.6%,差异无统计学意义（P〉0.05）;GP组与NP组中位生存时间分别为9.7、8.8个月,差异无统计学意义（P〉0.05）;两组毒副作用主要为血液学毒性,GP组Ⅲ~Ⅳ级血小板减少发生率显著高于NP组,差异有统计学意义（P〈0.05）,而Ⅲ~Ⅳ级白细胞减少发生率显著低于NP组,差异有统计学意义（P〈0.05）。结论 GP方案与NP方案治疗晚期非小细胞癌临床疗效均确切可靠,二者毒性作用均可耐受,临床可根据患者情况选择合理的治疗方案。

Objective To explore the effect of GP regimen（Cisplatin combined with Gemcitabine） and NP regimen（Cisplatin combined with Navelbine） in treatment of non-small cell lung cancer.Methods The data of 86 cases with non-small cell lung cancer were retrospectively analyzed with 45 patients in GP group and 41 patients in NP group.Clinical effect,sur vival time and toxic side effects were compared between two groups.Results The effective rates in GP group and NP group were 44.4% and 36.6% respectively,the difference was not statistically significant（P〉0.05）;The difference of median survival time between two groups was not statistically significant（9.7 months vs 8.8 months,P〉0.05）;Hematological toxicity was the major toxic side effect in two groups.The occurrence rate of grade Ⅲ/Ⅳ thrombocytopenia in GP group was much higher than that in NP group,the difference was statistically significant（P〈0.05）,but the incidence rate of grade Ⅲ/Ⅳ leucopenia in GP group was much lower than that in NP group,the difference was statistically significant（P〈0.05）.Conclusion GP regimen and NP regimen for treatment of non-small cell lung cancer are equally effective and well tolerat ed.Patients can choose the rational regimen according to the conditions.